Literature DB >> 9882707

A molecular basis for the different local anesthetic affinities of resting versus open and inactivated states of the sodium channel.

H L Li1, A Galue, L Meadows, D S Ragsdale.   

Abstract

Voltage-gated sodium channels are inhibited by local anesthetic drugs. This inhibition has complex voltage- and frequency-dependent properties, consistent with a model in which the sodium channel has low affinity for local anesthetics when it is in resting states and higher affinity when it is in open or inactivated states. Two residues, a phenylalanine (F1710) and a tyrosine (Y1717), in transmembrane segment IVS6 of the channel alpha subunit are critical for state-dependent block. We examined how these residues determine channel sensitivity to local anesthetics by introducing mutations that varied their size, hydrophobicity, and aromaticity. Block of resting channels by tetracaine was correlated with hydrophobicity at position 1710, as if hydrophobic drug-receptor interactions stabilize binding to resting states. In contrast, drug action on open or inactivated channels required an aromatic residue at this position. We propose that the native phenylalanine at position 1710 stabilizes drug binding to open or inactivated states by either cation-pi or aromatic-aromatic interactions between the aromatic side chain of the amino acid and charged or aromatic moieties on the drug molecule. We also consider the alternative possibility that mutations at this position affect drug action by either altering access to the receptor or by allosteric changes in receptor conformation. Mutations at position 1717 also altered drug action; however, these effects were not well-correlated with the size, hydrophobicity, or aromaticity of the substituted amino acid. These results suggest that the residue at this position does not contribute directly to the drug receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882707     DOI: 10.1124/mol.55.1.134

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  51 in total

1.  Halogen substituents on the aromatic moiety of the tetracaine scaffold improve potency of cyclic nucleotide-gated channel block.

Authors:  Sarah R Kirk; Adriana L Andrade; Kenneth Melich; Evan P Jackson; Elysia Cuellar; Jeffrey W Karpen
Journal:  Bioorg Med Chem Lett       Date:  2011-08-27       Impact factor: 2.823

2.  Lidocaine partially depolarizes the S4 segment in domain IV of the sodium channel.

Authors:  Michael F Sheets; Tiehua Chen; Dorothy A Hanck
Journal:  Pflugers Arch       Date:  2010-10-28       Impact factor: 3.657

3.  Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels.

Authors:  Hai Huang; Silvia G Priori; Carlo Napolitano; Michael E O'Leary; Mohamed Chahine
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-12       Impact factor: 4.733

Review 4.  Bacterial voltage-gated sodium channels (BacNa(V)s) from the soil, sea, and salt lakes enlighten molecular mechanisms of electrical signaling and pharmacology in the brain and heart.

Authors:  Jian Payandeh; Daniel L Minor
Journal:  J Mol Biol       Date:  2014-08-23       Impact factor: 5.469

Review 5.  Interactions of local anesthetics with voltage-gated Na+ channels.

Authors:  C Nau; G K Wang
Journal:  J Membr Biol       Date:  2004-09-01       Impact factor: 1.843

6.  Charge at the lidocaine binding site residue Phe-1759 affects permeation in human cardiac voltage-gated sodium channels.

Authors:  Megan M McNulty; Gabrielle B Edgerton; Ravi D Shah; Dorothy A Hanck; Harry A Fozzard; Gregory M Lipkind
Journal:  J Physiol       Date:  2007-03-15       Impact factor: 5.182

7.  Mechanisms of action of ligands of potential-dependent sodium channels.

Authors:  D B Tikhonov
Journal:  Neurosci Behav Physiol       Date:  2008-07-18

8.  Accessibility of mid-segment domain IV S6 residues of the voltage-gated Na+ channel to methanethiosulfonate reagents.

Authors:  Akihiko Sunami; Arlene Tracey; Ian W Glaaser; Gregory M Lipkind; Dorothy A Hanck; Harry A Fozzard
Journal:  J Physiol       Date:  2004-10-07       Impact factor: 5.182

9.  Structural determinants of drugs acting on the Nav1.8 channel.

Authors:  Liam E Browne; Frank E Blaney; Shahnaz P Yusaf; Jeff J Clare; Dennis Wray
Journal:  J Biol Chem       Date:  2009-02-19       Impact factor: 5.157

10.  Inhibition of skeletal muscle sodium currents by mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile.

Authors:  Annamaria De Luca; Sophie Talon; Michela De Bellis; Jean-François Desaphy; Carlo Franchini; Giovanni Lentini; Alessia Catalano; Filomena Corbo; Vincenzo Tortorella; Diana Conte-Camerino
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-25       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.